Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novo Nordisk A/S
Age
55–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female
Age above or equal to 55 years at the time of signing informed consent
Body mass index (BMI) greater than or equal to (\>=) 25.0 kilograms per meter square (kg/m\^2)
Established CVD as evidenced by at least one of the following:
1. Prior myocardial infarction
2. Prior stroke (ischemic or haemorrhagic stroke)
3. Symptomatic peripheral arterial disease (PAD) defined as at least one of the following:
1. Intermittent claudication with an ankle-brachial index (ABI) less than (\<) 0.85 at rest
2. Intermittent claudication with a \>= 50% stenosis in a lower extremity peripheral artery documented by X-ray angiography, magnetic resonance (MR) angiography, computed tomography (CT) angiography or Doppler ultrasound
3. Prior revascularization procedure of a lower extremity peripheral artery
4. Lower extremity amputation at or above ankle due to atherosclerotic disease (excluding e.g., trauma or osteomyelitis)
Diagnosed with type 2 diabetes mellitus (T2D) \>= 180 days before screening
HbA1c 6.5%-10% (47-86 millimoles per mole \[mmol/mol\]) (both inclusive), as measured by central laboratory at screening
Treatment with either:
1. Lifestyle intervention alone
2. 1-3 marketed oral antidiabetic drugs (OADs) (metformin, α-glucosidase inhibitors (AGI), glinides, sodium-glucose co-transporter 2 inhibitor (SGLT2i), dipeptidyl peptidase 4 (DPP4)-inhibitors, thiazolidinediones, or sulphonylureas (SU) as a single agent or in combination) according to local label
3. Basal insulin alone or in combination with up to two marketed OADs, all according to local label
You may not be if
Myocardial infarction, stroke, hospitalization for unstable angina pectoris or transient ischaemic attack within 60 days before screening
Planned coronary, carotid or peripheral artery revascularisation known on the day of screening
Heart failure classified as being in New York Heart Association (NYHA) Class IV at screening
Treatment with any glucagon-like peptide-1 (GLP-1) receptor agonist (RA) or a medication with GLP-1 activity within 90 days before screening
End stage renal disease defined as estimated glomerular filtration rate (eGFR) \< 15 millileters per minutes per 1.73\^2 (mL/min/1.73 m\^2), as measured by the central laboratory at screening
Chronic or intermittent haemodialysis or peritoneal dialysis
